FDAClass IIJanuary 15, 2025

Duloxetine Delayed-Release Capsules USP 20 mg recall: Impurity Out of Spec

Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60

Why was Duloxetine Delayed-Release Capsules USP 20 mg recalled?

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

What should I do if I have this product?

The recall is ongoing. Follow the firm and FDA instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lot # DT2023003A, DT2023007A, DT2023008A, exp. date Jan-25

Product
Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
Recalling firm
Rising Pharma Holding, Inc.
Quantity
73,680 bottles
Distribution
Nationwide
Recall date
January 15, 2025
Classification
Class II
Status
Ongoing
Agency
FDA (drug)
Open FDA enforcement record Latest recalls